Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Rhythm Pharmaceuticals (RYTM) EPS (Weighted Average and Diluted) (2019 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed EPS (Weighted Average and Diluted) for 7 consecutive years, with -$0.73 as the latest value for Q4 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) fell 1.39% to -$0.73 in Q4 2025 year-over-year; TTM through Dec 2025 was -$3.11, a 28.34% increase, with the full-year FY2025 number at -$3.11, up 28.34% from a year prior.
  • EPS (Weighted Average and Diluted) was -$0.73 for Q4 2025 at Rhythm Pharmaceuticals, up from -$0.82 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.9 in Q1 2021 to a low of -$2.35 in Q1 2024.
  • A 5-year average of -$0.78 and a median of -$0.76 in 2023 define the central range for EPS (Weighted Average and Diluted).
  • Peak YoY movement for EPS (Weighted Average and Diluted): skyrocketed 215.38% in 2021, then crashed 216.67% in 2022.
  • Rhythm Pharmaceuticals' EPS (Weighted Average and Diluted) stood at -$0.9 in 2021, then grew by 17.78% to -$0.74 in 2022, then increased by 5.41% to -$0.7 in 2023, then fell by 2.86% to -$0.72 in 2024, then fell by 1.39% to -$0.73 in 2025.
  • Per Business Quant, the three most recent readings for RYTM's EPS (Weighted Average and Diluted) are -$0.73 (Q4 2025), -$0.82 (Q3 2025), and -$0.75 (Q2 2025).